Login to Your Account



NewCo News

Cellworks Taps Semiconductor Expertise to Boost Predictability

By Trista Morrison
Staff Writer

Friday, May 11, 2012
With $7.5 million of Series A funding in hand and a Series B round on deck, Cellworks Group Inc. is advancing lead drug CWG952 toward the clinic for rheumatoid arthritis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription